AI Verdict
MBLY has stronger fundamentals based on our AI analysis.
MBRX vs MBLY Fundamental Comparison
| Metric | MBRX | MBLY |
|---|---|---|
| Revenue | $0.0 | $1.9B |
| Net Income | $-33.6M | $-392.0M |
| Net Margin | N/A | -20.7% |
| ROE | -223.6% | -3.3% |
| ROA | -151.7% | -3.1% |
| Current Ratio | 1.41x | 6.10x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | N/A | $-0.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MBRX vs MBLY: Frequently Asked Questions
Is MBRX or MBLY a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MBLY has stronger fundamentals. MBRX is rated STRONG SELL (95% confidence) while MBLY is rated HOLD (62% confidence). This is not investment advice.
How does MBRX compare to MBLY fundamentally?
Moleculin Biotech, Inc. has ROE of -223.6% vs Mobileye Global Inc.'s -3.3%. Net margins are N/A vs -20.7% respectively.
Which stock pays higher dividends, MBRX or MBLY?
MBRX has a dividend yield of N/A or no dividend while MBLY has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MBRX or MBLY for long term?
For long-term investing, consider that MBRX has STRONG SELL rating with 95% confidence, while MBLY has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MBRX vs MBLY?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MBRX vs MBLY, the AI consensus favors MBLY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.